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Among the genetic causes/predisposing factors for inflammatory keratinization disorders, several 35 
factors are associated with autoinflammatory mechanisms. Here we review these inflammatory 36 
keratinization disorders with autoinflammatory pathogenic mechanisms and advocate the novel, 37 
unique concept of “autoinflammatory keratinization diseases” (AIKD). We propose the following 38 
definition of AIKD. (1) The primary and main inflammation sites are the epidermis and the upper 39 
dermis. (2) The inflammation in the epidermis and the upper dermis leads to hyperkeratosis, which 40 
is the main and characteristic phenotype of AIKD. (3) AIKD have primary genetic causative 41 
factors associated with the hyperactivation of innate immunity (autoinflammation), mainly in the 42 
epidermis and the upper dermis. (4) The concept of AIKD subsumes diseases with mixed 43 
pathomechanisms of autoinflammation and autoimmunity. AIKD have genetic abnormalities as 44 
causative factors, and hyperactivation of the innate immune system resulting from those genetic 45 
defects plays an important role in the pathogenesis. 46 
 47 
Recently, a number of CARD14 gain-of-function variants/mutations have been reported as 48 
predisposing factors for psoriasis vulgaris (plaque-type psoriasis) and psoriatic arthritis.1, 2 Jordan 49 
et al.1 found a rare de novo gain-of-function variant in CARD14, p.Glu138Ala, in a sporadic case 50 
of severe early-onset generalized pustular psoriasis (GPP). Sugiura et al.3 reported a rare variant in 51 
CARD14, p.Asp176His, to be a significant predisposing factor for GPP with preceding or 52 
concurrent psoriasis vulgaris lesions, and this variant underlies approximately 20% of GPP cases 53 
with psoriasis vulgaris in the Japanese population. CARD14 variants are also disease susceptibility 54 
factors of European palmoplantar pustular psoriasis (palmoplantar pustulosis).4  55 
 56 
CARD14 encodes the CARD family member “caspase recruitment domain family, member 14” 57 
(CARD14). CARD14 is expressed and localized mainly in the skin, especially in keratinocytes.1 58 
Psoriasis-causative CARD14 mutations enhance NF-B activation and upregulate a subset of 59 
psoriasis-associated genes in keratinocytes (Fig 1).1, 2 The CARD14 mutations in the keratinocytes 60 
are thought to be responsible for pathogeneses and clinical manifestations of inflammatory 61 
 3 
keratinization diseases with CARD14 mutations. However, we cannot rule out the possibility that 62 
CARD14 mutations in immune cells other than keratinocytes may be involved in the pathogenesis. 63 
 64 
Deficiency in interleukin 36 receptor antagonist (IL-36Ra) due to mutations in IL36RN has been 65 
reported as a genetic cause of familial GPP with recessive inheritance in the Tunisian population.5 66 
Onoufriadis et al.6 reported that IL36RN mutations underlie three sporadic European GPP patients. 67 
Later, it was elucidated that most sporadic GPP patients without psoriasis vulgaris skin symptoms 68 
have IL36RN mutations as a cause of the disease.7 Hussain et al.8 recommended that GPP patients 69 
with the clinical triad of early onset, systemic inflammation and absence of concurrent psoriasis 70 
vulgaris be screened for IL36RN mutations, based on the results of their GPP cohort study. 71 
Mutations in IL36RN have been reported in patients with certain other psoriasis-related diseases, 72 
acrodermatitis continua of Hallopeau, severe acute generalized exanthematous pustulosis and 73 
impetigo herpetiformis. 74 
 75 
IL-36Ra expression is seen primarily in the skin. IL-36Ra works as an antagonist to the 76 
interleukin-1 family members IL-36 ,  and (Fig 1). Thus, deficiency of IL-36Ra due to 77 
IL36RN loss-of-function mutations is thought to result in the acceleration of IL-36-driven skin 78 
inflammation. 79 
 80 
These facts clearly demonstrate that, among psoriasis and its related disorders, rare subtypes, GPP, 81 
impetigo herpetiformis and acrodermatitis continua with IL36RN mutations, and GPP and 82 
palmoplantar pustular psoriasis (palmoplantar pustulosis) with CARD14 variants are thought to be 83 
catagorizable as AIKD. 84 
 85 
Pityriasis rubra pilaris (PRP) is an inflammatory erythematous keratinization disorder showing 86 
perifollicular erythema often with confluent configurations, follicular plugging, pityriasis capitis 87 
and palmoplantar hyperkeratosis. Most PRP cases are regarded as sporadic cases, although 88 
 4 
familial occurrence is also seen, particularly in one subtype, type V (atypical juvenile type). 89 
Notably, the skin eruptions in type V PRP first appear in infancy or early childhood and tend to run 90 
a chronic course with no sustained clearance of the skin. Gain-of-function mutations in CARD14 91 
were identified in some autosomal dominant familial cases of PRP. In our recent study of 22 92 
patients with PRP, all three patients with PRP type V were found to have CARD14 mutations.9 In 93 
addition, detailed clinical features of the reported PRP cases with CARD14 mutations in the 94 
literature were reviewed and it was confirmed that all the PRP cases with CARD14 mutations in 95 
the literature were affected with type V PRP.9 To date, eight heterozygous mutations in CARD14 96 
have been reported in patients with type V PRP. We propose that PRP type V, the atypical juvenile 97 
type, is a distinct variant of PRP that is caused by CARD14 mutations9 and should be regarded as 98 
an AIKD. 99 
 100 
Keratosis lichenoides chronica (KLC) is a rare inflammatory keratinization disorder of unknown 101 
pathomechanism. Characteristic clinical features of KLC are tiny papules on the trunk and 102 
extremities, which become confluent, resulting in linear and reticulate patterns, and seborrheic 103 
dermatitis-like eruptions on the face. The lesions have a chronic and often progressive course. 104 
Recently, a distinct gain-of-function mutation in the inflammasome sensor protein, NLR family, 105 
pyrin domain containing protein 1 (NLRP1) was found as the cause in a family with KLC.10 106 
 107 
NLRP1 is considered to be the most prominently expressed inflammasome sensor in human skin, 108 
and keratinocytes express all other inflammasome components, including CASP1, ASC, IL-1 109 
and IL-18.10 Evidence for spontaneous inflammasome activation by the KLC-causing NLRP1 110 
mutation in patients’ keratinocytes has been provided, and inflammasome-dependent IL-1 111 
cytokines have been demonstrated to cause familial KLC.10 In this context, we now consider that 112 
autoinflammatory mechanisms play an important role in the pathogenesis of KLC, at least in that 113 
of familial KLC. 114 
 115 
 5 
Here we advocate for the new disease category AIKD, which describes inflammatory 116 
keratinization disorders with autoinflammatory mechanisms as their predominant etiology, 117 
including minor subsets of psoriasis and related diseases, PRP type V and KLC, as mentioned 118 
above (Table I). Inflammatory hyperkeratotic skin lesions are not common in conventional 119 
autoinflammatory diseases. Thus, although AIKD is thought to have autoinflammatory pathogenic 120 
mechanisms, unique pathomechanisms with inflammation that involves epidermal keratinocytes 121 
and results in hyperkeratosis are assumed in AIKD. As the causes/predisposing factors for 122 
inflammatory keratinization disorders come to be successively elucidated, a larger number of 123 
disorders will be categorized into AIKD. 124 
 125 
  126 
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Figure legend 169 
 170 
FIG 1. Pathways and processes of inflammatory responses induced by CARD14 gain-of-function 171 
mutations and IL-36Ra deficiency. 172 
Mutant CARD14 hyperactivates NFB (red arrows with *), leading to the secretion of 173 
chemokines/cytokines, IL-36, IL-8, CXCL1, CXCL2 and CCL20, from the keratinocyte and 174 
resulting in the activation of neutrophils and dendritic cells in the dermis. In addition, Th1 and 175 
Th17 cells are induced and Th1 cytokines and IL-17 are secreted. IL-36Ra deficiency (red x-mark 176 
with *) causes up-regulation of IL-36 signaling, also leading to the secretion of 177 
chemokines/cytokines from the keratinocytes. Up-regulated IL-36 signaling finally activates 178 
neutrophils and dendritic cells and promotes Th1 and Th17 cell polarization. Black arrows: 179 
secretion or activation; brown arrows: cell differentiation or chemotaxis; ⊥: inhibition. 180 
 181 
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TABLE I. Inflammatory keratinization disorders included in AIKD and their pathogeneses 183 
Disease Genetic causative factor 
(frequency) 
Pathogenic inflammatory mechanisms 
and pathways in keratinocytes 
IL36Ra-related pustulosis   
generalized pustular 
psoriasis (GPP) without PV 
IL36RN mutations (prevalent) IL-36→MyD88→NFkB/MAPK 
→TNF, IL-1, IL-8, IL-17, IL-36, CXCL1, 
CXCL2, CCL20 impetigo herpetiformis IL36RN mutations (prevalent) 
acrodermatitis continua IL36RN mutations (not rare) 
CARD14-mediated pustular 
psoriasis 
  
 
 
CARD14→NFkB→IL-36, IL-8, CXCL1, 
CXCL2, CCL20 
GPP with PV CARD14 variants (not rare) 
palmoplantar pustular 
psoriasis (palmoplantar 
pustulosis) 
 
CARD14 variants (not rare) 
Pityriasis rubra pylaris (PRP)  
PRP type V CARD14 mutations (prevalent) 
PRP other types CARD14 variants (rare) 
Keratosis lichenoides chronica 
(familial) 
NLRP1 mutation (unknown) NLRP1→inflammasome 
→caspase-1→IL-1 
→TNF, GM-CSF, IL-36 
 184 
 185 
